News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Management of Beta-Thalassemia

EP. 1: Overview of Beta Thalassemia

January 31st 2020

EP. 2: Prevalence and Clinical Presentation of B-Thalassemia

January 31st 2020

EP. 3: β-Thalassemia Severity and Impact on Patients

January 31st 2020

EP. 4: Impact of β-Thalassemia on the Providers

January 31st 2020

EP. 5: Current Approaches for Beta-Thalassemia

January 31st 2020

EP. 6: The Role of Transfusion for Beta-Thalassemia

January 31st 2020

EP. 7: Understanding Transfusion for Beta-Thalassemia

January 31st 2020

EP. 8: Iron Dysregulation & Allogeneic Stem Cell Transplantation

January 31st 2020

EP. 9: Approval of Novel Therapy for Beta-Thalassemia

January 31st 2020

EP. 10: End Points of Phase III Study for Beta-Thalassemia

January 31st 2020

EP. 11: Future Impact of the Novel Therapy for Beta-Thalassemia

January 31st 2020

EP. 12: The Potential for Gene Therapy in Beta-Thalassemia

January 31st 2020

EP. 13: The Process for Gene Therapy in Beta-Thalassemia

January 31st 2020

EP. 14: The Cost and Safety of Gene Therapy in Beta-Thalassemia

January 31st 2020

EP. 15: Pipeline Agents for the Treatment of Beta-Thalassemia

January 31st 2020

EP. 16: Final Thoughts on the Treatment of Beta-Thalassemia

January 31st 2020

Trending on OncLive

FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC

FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in ccRCC

Subgroup Analyses Confirm Clinically Meaningful Revumenib Responses in AML Across Mutational Profiles

Amivantamab in recurrent/metastatic head and neck squamous cell carcinoma after immune checkpoint inhibitor and chemotherapy

Data Support Luspatercept at Maximum-Approved Dose for Transfusion-Dependent Lower-Risk MDS